Want to see JP:7681 full AI Analyst Report?
LEOCLAN Co. Ltd. (7681) AI Stock Analysis
Top Page
LEOCLAN Co. Ltd.
(TSE/TYO:7681)
The score is held back primarily by weak recent cash generation (negative operating and free cash flow) and a high valuation (P/E ~54). These are partially offset by a very strong, low-risk balance sheet (near-zero debt) and a mildly positive technical setup with price above key moving averages.
LEOCLAN Co. Ltd. (7681) vs. iShares MSCI Japan ETF (EWJ)
- Market Cap
- JPY 5.68B
- Dividend Yield
- 1.77%
- Average Volume (3M)
- 2,316
- Price to Earnings (P/E)
- 49.2
- Beta (1Y)
- -0.25
- Revenue Growth
- 89.99%
- EPS Growth
- -56.28%
- Country
- Japan
- Employees
- 155
- Sector
- Healthcare
- Sector Strength
- 51
- Industry
- Medical - Distribution
LEOCLAN Co. Ltd. Business Overview & Revenue Model
Company Description
LEOCLAN Co.,Ltd. operates as a medical equipment trading firm, addressing diverse needs across medical care, welfare, and general health sectors. Its operations are structured into three main divisions: Medical Total Solutions Business, Remote Image...
LEOCLAN Co. Ltd. Financial Statement Overview
Summary
Financials are mixed: a strong balance sheet with effectively no debt supports stability, but income performance is only average due to volatile revenue and thin margins, and cash flow is a key concern with negative operating cash flow in 2025 and negative free cash flow in 2024–2025.
Income Statement
54NeutralBalance Sheet
82Very PositiveCash Flow
38Negative| Breakdown | TTM | Sep 2025 | Sep 2024 | Sep 2023 | Sep 2022 | Sep 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 40.47B | 21.49B | 19.80B | 26.63B | 29.77B | 26.35B |
| Gross Profit | 4.99B | 2.74B | 2.62B | 2.82B | 3.06B | 2.73B |
| EBITDA | 916.42M | 400.58M | 375.47M | 553.93M | 789.05M | 692.94M |
| Net Income | 115.68M | 152.78M | 136.06M | 271.31M | 437.05M | 390.98M |
Balance Sheet | ||||||
| Total Assets | 22.30B | 10.91B | 10.66B | 14.75B | 13.52B | 13.02B |
| Cash, Cash Equivalents and Short-Term Investments | 8.78B | 4.78B | 5.57B | 5.54B | 5.48B | 5.41B |
| Total Debt | 4.90B | 7.19M | 12.57M | 5.67M | 99.82M | 133.54M |
| Total Liabilities | 16.28B | 5.09B | 4.93B | 9.02B | 7.98B | 7.86B |
| Stockholders Equity | 5.83B | 5.63B | 5.57B | 5.57B | 5.38B | 5.03B |
Cash Flow | ||||||
| Free Cash Flow | -116.70M | -116.70M | 17.72M | 291.06M | 215.57M | 1.28B |
| Operating Cash Flow | -86.65M | -86.65M | 33.08M | 341.56M | 242.36M | 1.30B |
| Investing Cash Flow | -619.82M | -619.82M | 100.75M | -82.01M | -49.96M | -42.13M |
| Financing Cash Flow | -100.73M | -100.73M | -97.22M | -202.31M | -120.93M | -298.01M |
LEOCLAN Co. Ltd. Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For JP:7681, the sentiment is Negative. The current price of 960.00 is below the 20-day moving average (MA) of 970.65, below the 50-day MA of 980.57, and above the 200-day MA of 920.46, indicating a neutral trend. The MACD of -3.76 indicates Negative momentum. The RSI at 46.53 is Neutral, neither overbought nor oversold. The STOCH value of 83.09 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for JP:7681.
LEOCLAN Co. Ltd. Peers Comparison
Overall Rating
- JP:768156Neutral
JP:375045Neutral
JP:497842Neutral
JP:777442Neutral
JP:459940Underperform
JP:777626Underperform
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| JP:7681 | 56Neutral | JPY 5.69B | 49.16 | ― | 1.77% | 89.99% | -56.28% |
| Sector * | 51Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
| JP:3750 | 45Neutral | JPY 7.14B | -12.75 | ― | ― | 15.47% | 69.34% |
| JP:4978 | 42Neutral | JPY 13.03B | -26.58 | ― | ― | -18.71% | -246.54% |
| JP:7774 | 42Neutral | JPY 25.54B | -58.02 | ― | ― | 3.43% | -53.59% |
| JP:4599 | 40Underperform | JPY 8.71B | -4.68 | ― | ― | ― | 4.85% |
| JP:7776 | 26Underperform | JPY 7.43B | -6.49 | ― | ― | -56.16% | 3.12% |
* Healthcare Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| JP:7681 | LEOCLAN Co. Ltd. | 960.00 | -144.87 | -13.11% | |
| JP:3750 | Cytori Cell Research Institute, Inc. | 800.00 | -40.00 | -4.76% | |
| JP:4599 | StemRIM Inc. | 139.00 | -134.00 | -49.08% | |
| JP:4978 | ReproCELL Inc. | 122.00 | -51.00 | -29.48% | |
| JP:7774 | Japan Tissue Engineering Co., Ltd. | 629.00 | 153.00 | 32.14% | |
| JP:7776 | CellSeed Inc. | 188.00 | -249.00 | -56.98% |
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Aug 20, 2026